NCT02072213

A PK Study GL2702 GLARS-NF1 and Omix Ocas® in Healthy Male Volunteers

A Randomized, Open-label, Single-dose, Four-sequence, Four -Period Crossover Study to Investigate The Pharmacokinetics of GL2702 GLARS-NF1 and Omix Ocas® in Healthy Male Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 36 (actual)
• Sponsor: GL Pharm Tech Corporation · Industry
• Sex: Male
• Age: 20 Years – 45 Years
• Healthy volunteers: Accepted

Summary

Study to Investigate The Pharmacokinetics of GL2702 GLARS-NF1 and Omix Ocas® in Healthy Male Volunteers

Detailed description

GL2702 GLARS-NF1 tablet is controlled released formulation which is invented by GL Pharm Tech Corp.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	GL2702 GLARS-NF1	0.4mg once a day
DRUG	Omix Ocas	0.4mg once a day

Timeline

• Start date: 2013-08-01
• Primary completion: 2014-01-01
• Completion: 2014-01-01
• First posted: 2014-02-26
• Last updated: 2019-01-10

Locations

1 site across 1 country: South Korea